Charest A. Optimizing an effective combination of the new microtubule targeting agent Lisavanbulin with standard of care therapy for glioblastoma in patient-derived xenograft pre-clinical models. Neuro Oncol 2021 Nov 27. pii: 6444804. doi: 10.1093.
PMID: 34850193